Understand what a "hot issue" IPO is, why it's oversubscribed, and how it attracts both long-term investors and speculators ...

The data illustrate that several patients remained on zenocutuzumab well beyond progression, including multiple patients who continued treatment for more than one- or two-years post-progression.

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Telangana High Court held that the income derived from tissue culture operations by the assessee qualifies as agricultural ...